Please assess the completion status of the following clinical trial:

Trial Title: Nasal Versus Venous Lorazepam for Control of Acute Seizures in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children presenting convulsing to the pediatric emergency or developing seizure while in casualty~* Age 6-14 years~Exclusion Criteria:~* Known hypersensitivity to any benzodiazepine~* Child has received any parenteral anti-convulsant within 1 hr prior to enrollment~* Presence of severe cardio-respiratory compromise or cardiac arrhythmias~* Presence of upper respiratory tract infection~* Presence of basal skull fracture causing cerebro-spinal fluid (CSF) rhinorrhea

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Intra-nasal lorazepam 0.1 mg/kg (max 4 mg)
- 2 (Type: ACTIVE_COMPARATOR): Intra-venous lorazepam 0.1 mg/kg (max 4 mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).